- Partnership underscores Medtronic's commitment to investing in innovative technologies that support physicians and patients from diagnosis to treatment
- CathWorks' FFRangio® System provides diagnostic and physiologic information through artificial intelligence to potentially disrupt traditional FFR and revolutionize the management of coronary artery disease
DUBLIN and KEFAR SAVA, Israel, July 12, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it has entered into a strategic partnership agreement with CathWorks, a privately held company headquartered in Kefar Sava, Israel, which aims to transform how coronary artery disease (CAD) is diagnosed and treated.